Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib

Healthy Volunteers Clinical Trial

Official title:

An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Varlitinib in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03368846
• Other study ID #: ASLAN001-018
• Status: Completed
• Phase: Phase 1
• Start date: November 23, 2017
• Est. completion date: December 14, 2017

Study information

• Verified date: September 2018
• Source: Aslan Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-centre, open-label, non-randomised, single oral dose study in healthy male subjects. It is planned to enrol a single cohort of 6 healthy male subjects to ensure data in 4 evaluable subjects.

Each subject will receive a single administration of 120 mg [14C] varlitinib oral suspension containing not more than (NMT) 2.9 MBq (79 µCi), in the fed state.

Description:

Subjects will be screened for eligibility to participate in the study up to 28 days before dosing. Subjects will be admitted to the clinical unit on the evening prior to IMP administration (Day 1) and will fast overnight for a minimum of 8 h. Subjects will be dosed on the morning of Day 1 following a light breakfast, and will remain resident in the clinic until up to 240 h after dosing (Day 11). It is planned that subjects will be released as a group when all subjects have achieved a mass balance cumulative recovery of >90%, or if <1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 h periods. In this case, collection of all samples (blood, urine and faeces) will cease and the subjects will undergo discharge assessments. If this criterion has not been met by all subjects on Day 11, the residency period may be extended by a further 48 h maximum (up to Day 13). If the criterion is still not met by Day 13, or if additional residency is not considered appropriate or necessary, then home collections of urine and/or faeces may be requested at the discretion of the investigator for individual subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: December 14, 2017
• Est. primary completion date: December 6, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy males of non-Asian descent

2. Aged 30 to 65 years

3. Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator

4. Must be willing and able to communicate and participate in the whole study

5. Must provide written informed consent

6. Must agree to use an adequate method of contraception (as defined in Section 9.4)

7. Must have regular bowel movements (ie, average stool production of =1 and =3 stools per day)

8. Subject is considered healthy on the basis of medical history, physical examination, ECG, vital signs and clinical laboratory assessments.

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the previous 3 months

2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee

3. Subjects with pregnant partners

4. Subjects who have previously been enrolled in this study

5. History of any drug or alcohol abuse in the past 2 years

6. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

7. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission

8. Users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

9. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study

10. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening

11. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1)

12. Neutrophil count <1.8 x109/L at screening

13. ALT and AST >1.25 x upper limit of normal range at screening

14. QT interval corrected for heart rate using Fridericia's formula (QTcF) > 450 msec at screening

15. Positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1)

16. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

17. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of <80 mL/min using the Cockcroft-Gault equation

18. History of clinically relevant cardiovascular, renal, hepatic, chronic respiratory or Gl disease, neurological or psychiatric disorder, as judged by the investigator

19. History of clinically relevant dermatological disease (eg eczema, psoriasis, drug rashes) or the presence of dermatological conditions at screening (eg acne, eczema, dermatitis etc)

20. Subjects with a history of cholecystectomy or gall stones

21. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

22. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active

23. Donation or loss of greater than 400 mL of blood within the previous 3 months

24. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days before IMP administration; with the exception of 4 g per day paracetamol [see Section 11.4]). Further exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.

25. Failure to satisfy the investigator of fitness to participate for any other reason

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Varlitinib
[14C]-Varlitinib

Locations

Country	Name	City	State
United Kingdom	Quotient Clinical Ltd	Nottingham

Sponsors (1)

Lead Sponsor	Collaborator
Aslan Pharmaceuticals

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mass balance recovery after a single oral dose of [14C] varlitinib	Mass balance recovery of [14C] varlitinib recovered in urine, faeces, and all excreta	Assessments will be made up to 13 days postdose
Primary	Metabolite profiling and structural identification of metabolites in plasma, urine and faeces	Identification of the chemical structure of metabolites	Assessments will be made up to 13 days postdose
Secondary	Routes and rates of elimination of [14C] varlitinib	Amount [14C] varlitinib excreted for urine and faeces	Assessments will be made up to 13 days postdose
Secondary	Determination of the chemical structure of the "major" metabolites of [14C] varlitinib	Identification of the chemical structure of each metabolite accounting for greater than 10%	Assessments will be made up to 13 days postdose
Secondary	Evaluation of whole blood:plasma concentration ratios for total radioactivity		Assessments will be made up to 13 days postdose
Secondary	PK of total radioactivity and varlitinib in plasma following a single oral dose of [14C] varlitinib	Peak Plasma Concentration (Cmax)	Assessments will be made up to 13 days postdose
Secondary	PK of total radioactivity and varlitinib in plasma following a single oral dose of [14C] varlitinib	Area under the plasma concentration versus time curve (AUC)	Assessments will be made up to 13 days postdose
Secondary	PK of total radioactivity and varlitinib in plasma following a single oral dose of [14C] varlitinib	Half life	Assessments will be made up to 13 days postdose
Secondary	PK of total radioactivity and varlitinib in plasma following a single oral dose of [14C] varlitinib	The time from dosing at which Cmax was apparent	Assessments will be made up to 13 days postdose
Secondary	Collect additional information on the safety and tolerability of varlitinib	Number of participants with abnormal laboratory values and/or adverse events	Assessments will be made up to 13 days postdose